Compare Neurocrine Biosciences Inc (NBIX) vs State Street PDR S&P Retail ETF (XRT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs State Street PDR S&P Retail ETF — how do they compare? Neurocrine Biosciences Inc trades at $161.94 (market cap $16.76B), while State Street PDR S&P Retail ETF trades at $89.79. The key difference: State Street PDR S&P Retail ETF is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| NBIX | XRT | |
|---|---|---|
Market Cap | $16.76B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $185.50 | $92.35 |
52-Week Low | $123.10 | $77.28 |
Enterprise Value | $16.78B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $163.41, up 2.25% today, with a bearish technical signal but strong fundamentals including a 39% revenue growth in Q2 2026 and a net income margin of 20.91%. Recent news highlights Phase 1 trial initiation for a GLP-1/GIP/glucagon receptor agonist and leadership appointments, supporting growth prospects.
The outlook is positive with an analyst consensus price target of $208.82, implying 28% upside, driven by robust earnings beats and pipeline advancements. Risks include clinical trial outcomes and competitive pressures in biopharma, but institutional buying and high analyst buy ratings (86.49%) reflect confidence in execution.
XRT trades at $90.82, up 1.08% with a bullish technical signal supported by moving averages. The ETF shows neutral oscillators like RSI at 57.83, while ADX indicates a strong trend. Support lies at $90 and resistance at $91. Recent retail sales growth and positive economic data provide a favorable backdrop, though sentiment is mixed amid inflation concerns.
Outlook is cautiously optimistic with retail sector momentum, but risks include consumer sentiment pressures and valuation headwinds. The ETF's diversification offers stability, yet macroeconomic shifts could impact performance. Investors should weigh technical strength against fundamental uncertainties in the retail space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About State Street PDR S&P Retail ETF
XRT is an equal-weighted ETF that tracks the U.S. retail sector. It provides diversified exposure to apparel, automotive, and online retailers, including well-known names like Amazon, Target, and Costco.
Read more on XRT →
